A multicenter, randomized, double‐blind, placebo‐controlled clinical trial revealed that the use of rosiglitazone (4 mg, orally administered twice daily), a thiazolidinedione ligand for PPARγ, effectively alleviated mild to moderate active IBD.33 The gene discussed is PPARG; the disease is inflammatory bowel disease.